Bu Julia Bing, Grabitz Stephanie D, Pfeiffer Norbert, Wasielica-Poslednik Joanna
Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
J Clin Med. 2022 Dec 30;12(1):289. doi: 10.3390/jcm12010289.
Graft failure after penetrating keratoplasty (PK) is a serious complication, especially in eyes with herpetic keratitis (HK). This study evaluated the prevalence and graft survival of herpes simplex virus type 1 (HSV-1) and varicella zoster virus (VZV) DNA in recipient corneas during PK. The retrospective study was performed at the Department of Ophthalmology at University Hospital in Mainz, Germany. We analyzed data from every patient who underwent PK between January 2020 and June 2021. According to our clinical routine, we performed HSV-1 and VZV polymerase chain reaction (PCR) on all excised corneal buttons regardless of the primary clinical diagnosis. We included 112 eyes of 112 consecutive patients who underwent PK. At the time of PK, 91 (81.25%) patients had no history of HK and 21 (18.75%) patients did. The recipient corneas of 91 patients without a history of HK tested positive for HSV-1 DNA in 12 (13.2%) eyes, for VZV DNA in 3 (3.3%) eyes, and for HSV-1 and VZV DNA simultaneously in 2 (2.2%) eyes. The recipient corneas of 21 patients with a preoperative history of HK tested positive for HSV-1 DNA in 13 (61.9%) eyes and VZV DNA in 1 (4.8%) eye. All patients with positive herpes DNA and no history of HK prior to PK received antiherpetic treatment and had a 100% graft survival rate after 1 year. We found herpesvirus DNA in 18.7% of recipient corneas without clinical suspicion or history of herpes keratitis. This suggests the need of routine HSV-1 and VZV PCR testing in all explanted corneas regardless of clinical suspicion, to detect, treat and prevent possible recurrence of herpes infection in corneal grafts and support graft survival.
穿透性角膜移植术(PK)后的移植失败是一种严重的并发症,尤其是在患有疱疹性角膜炎(HK)的眼睛中。本研究评估了PK期间受体角膜中单纯疱疹病毒1型(HSV-1)和水痘带状疱疹病毒(VZV)DNA的流行率和移植物存活率。这项回顾性研究在德国美因茨大学医院眼科进行。我们分析了2020年1月至2021年6月期间接受PK的每一位患者的数据。根据我们的临床常规,无论主要临床诊断如何,我们对所有切除的角膜植片进行了HSV-1和VZV聚合酶链反应(PCR)检测。我们纳入了112例连续接受PK的患者的112只眼睛。在进行PK时,91例(81.25%)患者无HK病史,21例(18.75%)患者有HK病史。91例无HK病史患者的受体角膜中,12只眼睛(13.2%)HSV-1 DNA检测呈阳性,3只眼睛(3.3%)VZV DNA检测呈阳性,2只眼睛(2.2%)HSV-1和VZV DNA同时检测呈阳性。21例术前有HK病史患者的受体角膜中,13只眼睛(61.9%)HSV-1 DNA检测呈阳性,1只眼睛(4.8%)VZV DNA检测呈阳性。所有PK前疱疹DNA阳性且无HK病史的患者均接受了抗疱疹治疗,1年后移植物存活率为100%。我们在18.7%的无临床疑似或疱疹性角膜炎病史的受体角膜中发现了疱疹病毒DNA。这表明,无论临床怀疑与否,都需要对所有切除的角膜进行常规HSV-1和VZV PCR检测,以检测、治疗和预防角膜移植中疱疹感染的可能复发,并支持移植物存活。